NCBiotech News

Durham-based BioSkryb Genomics has signed with Cooper Genomics to license BioSkryb’s proprietary genomic amplification technology for genetic testing of embryos prior to implantation in women seeking to become pregnant through in vitro fertilization.

North Carolina’s Research Triangle region is the nation’s fourth leading hub for biotechnology activity, trailing only Boston, San Francisco and San Diego, says Fierce Biotech, an online publication that covers the biotechnology and pharmaceutical industries.

Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis.

Guy Aday was the operations chief for the U.S. Consulate in Northern Afghanistan. After he injured his back and returned to the U.S. for back surgery and physical and vocational rehabilitation, he found a rewarding new career path in biotech via Alamance Community College.

The Foundation Fighting Blindness (FFB), with a spinoff startup headquartered in the Raleigh, is changing its executive leadership team.

Following two years of development, Astellas’ new late-stage clinical and commercial manufacturing plant officially opened its doors in Sanford.

Durham's Kriya Therapeutics just added $270 million to its coffers, bringing its total raised to date to roughly $450 million for novel gene therapies

MOLTOX, a family-owned pioneer in developing standardized genetic toxicology test products, just keeps getting stronger after 36 years in business from unlikely headquarters in the North Carolina mountain community of Boone.

Invitae, a California-based medical genetics company opening a lab and production facility in Morrisville, has commercially launched a new testing package for neurodevelopmental disorders in children.

A team of North Carolina scientists, with early grant support from NCBiotech, has developed an implantable scaffold resembling a “mini marshmallow” that produces and releases CAR-T cells for attacking cancerous tumors.

Seventeen months after negotiating a whopping $4 billion buyout deal with German pharma giant Bayer, AskBio CEO and co-founder Sheila Mikhail says the pioneering gene therapy company is hitting all its targets.

Impact investing is on the rise, and local pharmaceutical industry insiders presenting as part of a “who’s who” speaker lineup at LaunchBio’s recent Invest in Cures forum say it’s already paying off.

LaunchBio’s signature Invest in Cures forum will again convene leaders of major disease foundations and social venture funds on Feb. 24 at NCBiotech.

GreenLight Biosciences, which uses RNA-based technology for agricultural and human health applications, is adding more than 60,000 square feet and hiring some 16 more people at its RTP R&D operations.

Durham gene therapy company Kriya Therapeutics has purchased neighboring startup Warden Bio, for an undisclosed sum, to expand its rare diseases capabilities.